亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

335 Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells

作者
Whitney Lynn Gladney,Adina Vultur,Michael Thomas Schweizer,Joseph A. Fraietta,Andrew J. Rech,Carl H. June,Matthew O’Rourke,Amy Roberts,Hinel Patel,Jamie Rosen,Pam Hufner,Yanping Luo,David Maxwell Barrett,Thomas J. Fountaine,Karen Chagin
出处
期刊: 卷期号:: A353-A353 被引量:5
标识
DOI:10.1136/jitc-2022-sitc2022.0335
摘要

Background We previously reported preliminary safety and efficacy results from a multi-center Phase 1 trial of CART-PSMA-TGFβRDN T-cells (TmPSMA-01; NCT04227275) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Nine pts were dosed with TmPSMA-01 across three doses ranging from 1x107-3x108 CAR+ cells. Evidence of clinical activity was observed, however, two pts developed severe immune-mediated toxicity and experienced Grade (Gr) 5 events. These pts had no known clinically relevant risk-factors and demonstrated disparate pre- and post-infusion clinical courses. Translational research efforts to evaluate the mechanisms of immune-mediated toxicity to TmPSMA-01 were undertaken. Results are summarized herein. Methods Pt samples collected per clinical protocol were subjected to correlative analysis platforms. Longitudinal serum and peripheral blood specimens were evaluated for soluble factors by immunoassays and TmPSMA-01 kinetics by molecular techniques, respectively. Biomarker comparisons between patients with Gr5 events and those without were made. As available, pt tissues (tumor and autopsy samples) were evaluated for TmPSMA-01 infiltration by RNA-ISH. Additionally, an in vitro model of immune toxicity was applied to evaluate TmPSMA-01 product potency and new CAR candidates. Results Serum cytokines from all pts showed patterns consistent with an immune-effector response but pts with Gr5 events demonstrated an elevated inflammatory signature with higher levels of IL2, IL6, GM-CSF and IL-18, among others. Peripheral expansion of TmPSMA-01 was observed and kinetics correlated with cytokine response. Autopsy evaluation from one pt with a Gr5 event showed TmPSMA-01 lymph node tumor infiltration but no presence in the sampled brain, despite clinical presentation of immune effector cell associated neurotoxicity. Finally, in vitro modeling of immune-toxicity demonstrated higher cytokine levels in TmPSMA-01 cell products from Gr5 pts. Using the same assay, substituting CD2 for 41BB showed a reduction in cytokine levels without impacting efficacy. Conclusions Correlative studies from pts who demonstrated severe immune-mediated toxicity following TmPSMA-01 revealed trends toward patient-intrinsic hyperinflammation. Biomarker findings suggest a contribution of IL-18 to TmPSMA-01-associated cytokine response which can be further explored for toxicity management. Moreover, we found no evidence of on-target, off-tumor involvement in the examined tissues. While a clear mechanism explaining the excessive immune-mediated response in 2 pts following TmPSMA-01 is not fully elucidated, our preclinical data demonstrate potential risk mitigation by replacing the 41BB co-stimulatory domain with CD2. Knowledge gained from these studies supported the development of a next-generation PSMA-targeting CAR, TmPSMA-02, to improve safety while maintaining anti-tumor activity and will be explored in a multi-center, Ph1/2 trial for pts with mCRPC. Ethics Approval Patients were enrolled on a WCG Institutional Review Board (IRB) approved protocol, IRB#20191909, titled “A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Metastatic Castration Resistant Prostate Cancer.” This clinical study was designed and implemented, and the results of the trial reported in accordance with the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice with applicable local regulations and international guidances, including the 21 CFR and all ethical principles written in the Declaration of Helsinki. The clinical study protocol and the informed consent form (ICF) were both reviewed and approved by the properly chartered IRBs and Independent Ethics Committee before the study commenced. Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型的应助被369ninja采纳,获得10
5秒前
8秒前
369ninja发布了新的文献求助10
12秒前
懦弱的代云完成签到,获得积分10
22秒前
如意涵雁完成签到,获得积分10
27秒前
华仔的应助被爱学习的doge采纳,获得10
29秒前
英姑的应助被爱学习的doge采纳,获得10
42秒前
45秒前
45秒前
46秒前
51秒前
52秒前
52秒前
韩_发布了新的文献求助10
57秒前
彭于晏的应助被科研通管家采纳,获得10
59秒前
充电宝的应助被sun采纳,获得10
1分钟前
1分钟前
甜甜的文轩完成签到,获得积分10
1分钟前
爱笑的芝麻完成签到,获得积分10
1分钟前
阿双完成签到,获得积分10
1分钟前
sun发布了新的文献求助10
1分钟前
1分钟前
1分钟前
灵巧的绮琴完成签到,获得积分10
2分钟前
整齐的天问完成签到,获得积分10
2分钟前
Qian完成签到 ,获得积分10
2分钟前
细腻绮完成签到,获得积分10
2分钟前
2分钟前
天天快乐的应助被情深以挽采纳,获得10
2分钟前
369ninja发布了新的文献求助10
2分钟前
玛琳卡迪马完成签到,获得积分10
2分钟前
molihuakai的应助被科研通管家采纳,获得10
2分钟前
3分钟前
英俊的谷蓝完成签到,获得积分10
3分钟前
明理的璎完成签到,获得积分10
3分钟前
3分钟前
美丽的忆彤完成签到,获得积分10
3分钟前
Ava的应助被sun采纳,获得10
3分钟前
3分钟前
动听一德完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808444
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478958